Zura Bio to Acquire GigaGen for $100M
Ticker: ZURA · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1855644
| Field | Detail |
|---|---|
| Company | Zura Bio Ltd (ZURA) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, biotech, merger
TL;DR
Zura Bio buying GigaGen for $100M, deal expected Q3.
AI Summary
Zura Bio Ltd. announced on June 3, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of equity interests in GigaGen Inc. for an aggregate purchase price of $100 million. This acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition could significantly expand Zura Bio's pipeline and therapeutic capabilities in the biotechnology sector.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, introducing inherent risks.
Key Numbers
- $100 million — Acquisition Price (Aggregate purchase price for GigaGen Inc.)
Key Players & Entities
- Zura Bio Ltd. (company) — Acquiring company
- GigaGen Inc. (company) — Target company
- $100 million (dollar_amount) — Aggregate purchase price
- June 3, 2024 (date) — Date of report and agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on Zura Bio Ltd.'s entry into a definitive agreement to acquire GigaGen Inc.
What is the total consideration for the acquisition of GigaGen Inc.?
The aggregate purchase price for GigaGen Inc. is $100 million.
When is the acquisition of GigaGen Inc. expected to close?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
What is Zura Bio Ltd.'s former name and ticker symbol?
Zura Bio Ltd. was formerly known as JATT Acquisition Corp. and its ticker symbol is not explicitly mentioned in this filing excerpt.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-06-03 06:02:36
Key Financial Figures
- $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
- $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma
Filing Documents
- tm2416250d1_8k.htm (8-K) — 29KB
- tm2416250d1_ex99-1.htm (EX-99.1) — 13KB
- tm2416250d1_ex99-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-067368.txt ( ) — 278KB
- zura-20240603.xsd (EX-101.SCH) — 3KB
- zura-20240603_def.xml (EX-101.DEF) — 26KB
- zura-20240603_lab.xml (EX-101.LAB) — 36KB
- zura-20240603_pre.xml (EX-101.PRE) — 25KB
- tm2416250d1_8k_htm.xml (XML) — 5KB
01
Item 7.01. Regulation FD Disclosure. On June 3, 2024, Zura Bio Limited issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated June 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 3, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Kim Davis Chief Legal Officer